![Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile](https://www.researchgate.net/publication/351566802/figure/tbl2/AS:1023185684291584@1620957885816/Univariate-Analyses-of-Disease-Free-Survival-for-Identication-of-Potential-Prognostic_Q320.jpg)
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile
![Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile](https://www.researchgate.net/publication/265256897/figure/fig1/AS:616363374698498@1523963888378/Monoallelic-Becn1-loss-results-in-functionally-enriched-mammary-stem-and-progenitor-cell_Q320.jpg)
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile
![PDF) M103. A Case of Multiple Autoantibody-Related Treatment-Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Cerebellar Dysfunction Overlap Syndrome PDF) M103. A Case of Multiple Autoantibody-Related Treatment-Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Cerebellar Dysfunction Overlap Syndrome](https://i1.rgstatic.net/publication/373990875_M103_A_Case_of_Multiple_Autoantibody-Related_Treatment-Refractory_Chronic_Inflammatory_Demyelinating_Polyradiculoneuropathy_CIDP_and_Cerebellar_Dysfunction_Overlap_Syndrome/links/650781d8a69a4e6318149583/largepreview.png)
PDF) M103. A Case of Multiple Autoantibody-Related Treatment-Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Cerebellar Dysfunction Overlap Syndrome
![Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile](https://www.researchgate.net/profile/Yanying-Huo/publication/282131313/figure/fig1/AS:614316306862087@1523475829218/A-model-of-the-developmental-paths-of-PALB2-associated-breast-cancer-Under-normal_Q320.jpg)
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile
![Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF](https://i1.rgstatic.net/ii/profile.image/11431281166115381-1686168802235_Q64/Michael-Schad-4.jpg)
Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF
![Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile](https://www.researchgate.net/publication/265256897/figure/fig2/AS:616363374673934@1523963888780/Outgrowths-from-CD24-C-CD29-hi-Becn1-C-MEC-transplantation-display-increased_Q320.jpg)
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile
![Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile](https://c5.rgstatic.net/m/437738464651637/images/template/default/profile/profile_default_l.jpg)
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile
![PDF) Gray Matter Alteration in Cancer Survivors After Chemotherapy: An ALE Meta-Analysis of Voxel-Based Morphometry Studies PDF) Gray Matter Alteration in Cancer Survivors After Chemotherapy: An ALE Meta-Analysis of Voxel-Based Morphometry Studies](https://i1.rgstatic.net/ii/profile.image/1107524610719749-1641065852067_Q64/Majdi-Al-Qawasmeh-2.jpg)
PDF) Gray Matter Alteration in Cancer Survivors After Chemotherapy: An ALE Meta-Analysis of Voxel-Based Morphometry Studies
![PDF) M103. A Case of Multiple Autoantibody-Related Treatment-Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Cerebellar Dysfunction Overlap Syndrome PDF) M103. A Case of Multiple Autoantibody-Related Treatment-Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Cerebellar Dysfunction Overlap Syndrome](https://i1.rgstatic.net/ii/profile.image/1073399614947328-1632929819331_Q64/Mujtaba-Saeed-2.jpg)
PDF) M103. A Case of Multiple Autoantibody-Related Treatment-Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Cerebellar Dysfunction Overlap Syndrome
![Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile](https://www.researchgate.net/publication/265256897/figure/fig5/AS:616363378876432@1523963889342/Monoallelic-Becn1-loss-accelerates-WNT1-driven-tumorigenesis-and-gives-rise-to-mammary_Q320.jpg)
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology | Research profile
![Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF](https://i1.rgstatic.net/ii/profile.image/920868179959810-1596563491961_Q64/Ryan-Hutten.jpg)